CD8A and hepatocellular carcinoma: Specifically, we identified a subset of intermediate exhausted CD8+ T cells with a functionally antitumor phenotype, which expanded after HAIC treatment, accumulated in the TLS vicinity, and disseminated along fibroblastic tracks, suggesting that this CD8+ T subset could be effective biomarker for HAIC therapy in patients with advanced HCC.